Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project. The project applies proprietary nanonization technology to reduce rates of clinical attrition through improved drug solubility and bioavailability. The technology can significantly increase the number of drugs reaching the market, with patients around the world benefiting from the development of more efficient treatments.
The award certifies that the proposal is of an exceptional quality with a high degree of innovation and impact. The project was evaluated by an international panel of independent experts to ensure that the rigorous assessment criteria of excellence, impact, quality and efficiency of implementation were met.
Edward Hæggström, CEO of Nanoform said: “We are delighted that our proposal has received a Seal of Excellence from the European Commission. This endorsement of our unique nanonization technology demonstrates our ability to transform the pharmaceutical industry by helping companies around the world overcome complex drug development challenges.”
